Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wakamoto Pharmaceutical CoTSE:4512 +3.85%64 EV-to-EBIT is 20.80 as of Aug. 22, 2026, which is 67% above its 10-year median of 12.44. GuruFocus rates TSE:4512 with a GF Score™ of 64/100 and a GF Value™ of 円309.58 (Fairly Valued). The stock has 2 warning signs investors should review. Among 690 Drug Manufacturers companies, Wakamoto Pharmaceutical Co ranks worse than 59.13% on this metric.
Wakamoto Pharmaceutical Co (TSE:4512) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Wakamoto Pharmaceutical Co's Enterprise Value for the quarter that ended in Mar. 2026 was 円10,576 Mil.
Wakamoto Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円423 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wakamoto Pharmaceutical Co EV-to-EBIT Related Terms
Wakamoto Pharmaceutical Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Wakamoto Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wakamoto Pharmaceutical Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wakamoto Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Wakamoto Pharmaceutical Co's EV-to-EBIT falls into.
Wakamoto Pharmaceutical Co's current Enterprise Value is 円8,790 Mil.
Wakamoto Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円423 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wakamoto Pharmaceutical Co (TSE:4512) has a EV-to-EBIT of 20.80 as of Aug. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Wakamoto Pharmaceutical Co and its competitors. This is 67% above median its historical median of 12.44. According to the industry distribution chart, Wakamoto Pharmaceutical Co ranks #408 out of 690 companies in the Drug Manufacturers industry, placing it in the top 59.1%.
Is Wakamoto Pharmaceutical Co's EV-to-EBIT too high?
Wakamoto Pharmaceutical Co's current EV-to-EBIT of 20.80 is 67% above median its 10-year median of 12.44. The Drug Manufacturers industry median EV-to-EBIT is 15.12. Wakamoto Pharmaceutical Co's value of 20.80 is 37.6% above this industry median. Based on the distribution chart, Wakamoto Pharmaceutical Co ranks #408 out of 690 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Wakamoto Pharmaceutical Co has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Wakamoto Pharmaceutical Co's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Wakamoto Pharmaceutical Co ranks #408 out of 690 companies for EV-to-EBIT. This places Wakamoto Pharmaceutical Co in the lower half of its industry. The industry median EV-to-EBIT is 15.12. Wakamoto Pharmaceutical Co's value of 20.80 is 37.6% above this benchmark. While the company's 10-year median is 12.44 vs. the industry median of 15.12, Wakamoto Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.12, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wakamoto Pharmaceutical Co's current EV-to-EBIT of 20.80 is 37.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Wakamoto Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wakamoto Pharmaceutical Co's current EV-to-EBIT is 20.80, which is 67% above median its own 10-year median of 12.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wakamoto Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Wakamoto Pharmaceutical Co (TSE:4512) is currently considered Fairly Valued. The stock's GF Value™ is 円309.58, compared to a current price of 円297.00 — trading 4.1% below its estimated fair value. The current EV-to-EBIT is 20.80, which is 67% above median its 10-year median of 12.44 and 37.6% above the Drug Manufacturers industry median of 15.12. Wakamoto Pharmaceutical Co's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Wakamoto Pharmaceutical Co (TSE:4512), the current EV-to-EBIT is 20.80 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wakamoto Pharmaceutical Co (TSE:4512) Overvalued in 2026?
Based on GuruFocus' analysis, Wakamoto Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円297.00 is trading 4.1% below its estimated GF Value™ of 円309.58.
GuruFocus considers Wakamoto Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TSE:4512:
EV-to-EBIT: 20.80 (67% above median its 10-year median of 12.44)
GF Value™: 円309.58 vs. price of 円297.00 (4.1% below fair value)
Industry Position: 37.6% above the Drug Manufacturers median (#408 of 690)
No single metric tells the full story. See the TSE:4512 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wakamoto Pharmaceutical Co Ltd is the pharmaceutical company based in Japan. It is engaged in the research and development, production and sale of ethical drugs and non-prescription drugs. The company specializes in therapeutic and diagnostic agents for ophthalmic disorders. It offers Strong Wakamoto, a gastrointestinal drug for digestion, the intestinal function controlling, and nutritional supply.
64GF Score
Get the complete analysis for TSE:4512
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4512 has been successfully added to your 
